Wuhan Institute of Virology

Correcting and Enhancing the Global Understanding of the Role of Condoms in Reproductive Health — the Chinese Approach

Retrieved on: 
Tuesday, October 24, 2023
Survival, Birth, General assembly, AIDS, Reproductive Health Supplies Coalition, Wuhan Institute of Virology, Incidence, Health, Fertility, Life, LaTeX, HIV, Intellectual property, Gynaecology, Research, R, Condom, Public opinion, Ministry, Development, Speech, Male, RHSC, Chinese Academy of Sciences, Pregnancy, Social responsibility, Academic Model Providing Access to Healthcare (AMPATH), HBM, Safety, Under-occupied developments in China, Vertically transmitted infection, Infertility, Role, Infection, Abner Genece, Birth control, Virology

First -- Sexually transmitted diseases such as AIDS have caused great damage to the reproductive system, seriously threatening life and health. 

Key Points: 
  • This conference was jointly hosted by the Reproductive Health Supplies Coalition (RHSC) and the Ministry of Health of Ghana.
  • He was invited to attend the conference and delivered a keynote speech titled "Correcting and Enhancing the Global Understanding of the Role of Condoms in Reproductive Health — the Chinese Approach.
  • And continue to carry out innovative research and development in the global reproductive health field, and contribute to the Chinese plan to improve the global reproductive health level.
  • The company is committed to addressing the root causes of reproductive health issues in China and even around the world, correcting and enhancing the world's new understanding of condoms in terms of reproductive health and safety.

No NIH Money to EcoHealth Alliance, says AHF

Retrieved on: 
Tuesday, May 9, 2023
White House, Federal Government, Philanthropy, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Foundation, Communication, AHF, EcoHealth Alliance, Wuhan Institute of Virology, AIDS, AIDS Healthcare Foundation, NIH, Pharmaceutical industry, Virology

AIDS Healthcare Foundation strongly opposes the U.S. National Institutes of Health’s (NIH) decision to give more money to a group the U.S. Health and Human Services inspector general determined improperly used nearly $90,000 in previous grant funds and failed to obtain scientific documentation from the Wuhan Institute of Virology.

Key Points: 
  • AIDS Healthcare Foundation strongly opposes the U.S. National Institutes of Health’s (NIH) decision to give more money to a group the U.S. Health and Human Services inspector general determined improperly used nearly $90,000 in previous grant funds and failed to obtain scientific documentation from the Wuhan Institute of Virology.
  • AHF welcomes U.S. Rep. Morgan Griffin’s inquiry into NIH’s reckless decision and agrees with his position that no more contracts should be awarded to EcoHealth Alliance, which has collaborated with the Chinese government in blocking any serious investigation of the Wuhan Institute of Virology.
  • (See: https://morgangriffith.house.gov/news/documentsingle.aspx?DocumentID=402... )
    “The public is entitled to know how EcoHealth Alliance used public money from the NIH in its dealings with the Wuhan lab,” said Denys Nazarov, AHF Director of Global Policy and Communications.

New Evidence Backs Energy Department Lab Leak Conclusion

Retrieved on: 
Wednesday, March 1, 2023
Safety, Civilization, Gene, Doctor of Philosophy, Coronavirus, Wuhan Institute of Virology, GenBank, Laboratory, Politics, Virus, MERS, Research, The Wall Street Journal, Nipa, Publication, Infection, Synthetic biology, Human, Federation, Bangladesh Technical Education Board, Primary energy, Data, COVID, Vaccine, MD, Virology

SEATTLE, March 1, 2023 /PRNewswire/ -- This week the Wall Street Journal reported that a classified assessment from the Department of Energy concluded the COVID pandemic likely arose from a lab leak, although their confidence level in that assessment was said to be low.

Key Points: 
  • SEATTLE, March 1, 2023 /PRNewswire/ -- This week the Wall Street Journal reported that a classified assessment from the Department of Energy concluded the COVID pandemic likely arose from a lab leak, although their confidence level in that assessment was said to be low.
  • It is my analysis that a pandemic with a >10% lethal pathogen would likely end civilization as we know it."
  • The GenBank files were found in an agricultural rice sequencing dataset that had nothing to do with the MERS synthetic biology experiments.
  • The link to the paper, entitled: "Discovery of a Novel Merbecovirus DNA Clone Contaminating Agricultural Rice Sequencing Datasets from Wuhan, China."

Junshi Biosciences Announces Approval for Marketing of VV116 in China

Retrieved on: 
Monday, January 30, 2023
Treatment, RNA, Marketing, Zhejiang University, Chemistry, Ministry, Safety, Chinese Academy of Sciences, Drug discovery, RNA-dependent RNA polymerase, COVID-19, Ministry of Science and Technology (Vietnam), National Medical Products Administration, Omicron, III, SSE, Shanghai Institute of Technology, Patient, HIV disease progression rates, Physics, Viral load, RNA polymerase II, Severe acute respiratory syndrome coronavirus 2, HKEX, Development, Infection, Death, Approval, Toxicity, State Key Laboratories, Wuhan Institute of Virology, Diagnosis, Pharmaceutical industry, Science, Virology, Materia medica

SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”).

Key Points: 
  • SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”).
  • VV116 is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase (“RdRp”) of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect.
  • Preclinical studies have shown that VV116 exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity.
  • The study was led by academician Lanjuan LI, Director of the State Key Laboratory for Diagnosis & Treatment of Infectious Diseases (Zhejiang University) as primary investigator.

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

Retrieved on: 
Tuesday, December 20, 2022
Hospital, Severe acute respiratory syndrome coronavirus 2, Ritonavir, Neuropsychiatric Disease and Treatment, SIMM, Chinese Academy of Sciences, Patient, National Medical Products Administration, Trial of the century, Clinical trial, Central nervous system, Phase, Simcere Pharmaceutical, Drug discovery, Biotechnology, Capacity building, Fatality, Health, Degenerative disease, III, China-Japan Friendship Hospital, COVID-19, Medicine, Technology transfer, Safety, Post-exposure prophylaxis, National Center for Advancing Translational Sciences, Peking Union Medical College, Infection, Wuhan Institute of Virology, WIV, Cancer, NDA, Fear, FPI, Viral load, New Drug Application, Wuhan Jinyintan Hospital, Research, CAS, Pharmaceutical industry, Materia medica, Study, Virology

Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.

Key Points: 
  • Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.
  • This is to fulfill the Group's corporate mission of "providing today's patients with medicines of the future".
  • The Study has established a total of 43 clinical research centers in 20 provinces, municipalities and autonomous regions in China.
  • XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.

Datasea Unveils National Hailijia Air Sterilizer Product Campaign

Retrieved on: 
Thursday, December 8, 2022
Cloud, Wuhan Institute of Virology, Life, RNA, Airport, School, Staphylococcus epidermidis, Communication, Coronavirus, Disinfectant, Big data, Science, Marketing, Hospital, Escherichia coli, Digital technology, Vibration, Beijing Science and Technology University Gymnasium, TUV, Health, COVID-19, Transport, Atmosphere, Certification, UL, Research, Investment, MIIT, Patent, Sterilization, Communications and Information Technology Commission (Saudi Arabia), Attention, City, Agriculture, Cloud computing, Medical device, Virology

Today, the Company announced that it has unveiled the national Hailijia air sterilizer product campaign with an online event and offline product showcases in various cities in China, including Beijing, Shenzhen, Tianjin, Hangzhou and Shanghai.

Key Points: 
  • Today, the Company announced that it has unveiled the national Hailijia air sterilizer product campaign with an online event and offline product showcases in various cities in China, including Beijing, Shenzhen, Tianjin, Hangzhou and Shanghai.
  • During the product campaign, Datasea has entered into eight marketing and distribution agreements in order to expand the business and reach to customers and sell certain Hailijia air sterilizers and purifiers in China.
  • Hailijia air sterilizers have fifteen software copyrights in China, three patents in China and eight patent applications are pending in China.
  • Going forward, Datasea will continue to increase research and development investments in the field of acoustic intelligence and accelerate product upgrades.

Official Ground-breaking Ceremony of Wuhan Synthetic Biology Innovation Center & CABIO R&D Center Investment Project

Retrieved on: 
Thursday, October 20, 2022
Nutrient, Development, Wuhan Institute of Virology, Efficiency, Animal, Biotechnology, Synthetic biology, Breeding, Research, Multimedia, Technology, Industry, Central, Fermentation, Department of Industry, Innovation, Climate Change, Science, Research and Tertiary Education, Human, Fine chemical

WUHAN, China, Oct. 20, 2022 /PRNewswire/ --On October 19th, 2022, the investment project of the CABIO R&D Center officially commenced in Wuhan Optical Valley.

Key Points: 
  • WUHAN, China, Oct. 20, 2022 /PRNewswire/ --On October 19th, 2022, the investment project of the CABIO R&D Center officially commenced in Wuhan Optical Valley.
  • Upon the basis of the said investment project, the ground-breaking ceremony of the "Wuhan Synthetic Biology Innovation Center" project, a joint endeavor between CABIO Biotech (Wuhan) Co., Ltd, the Wuhan Institute of Industrial Innovation and Development and Hubei Yangtze Science Innovation Service Co. Ltd., was also held on the same day.
  • The Wuhan Synthetic Biology Innovation Center has been envisioned as the spearhead of the synthetic biology industry of the entire Central China region.
  • In light of advancements in synthetic biology, CABIO has increased investment in said field, constructed a synthetic biology lab, and initiated a series of technologically far-sighted research projects teeming with market potential.

Official Ground-breaking Ceremony of Wuhan Synthetic Biology Innovation Center & CABIO R&D Center Investment Project

Retrieved on: 
Thursday, October 20, 2022
Nutrient, Development, Wuhan Institute of Virology, Efficiency, Animal, Biotechnology, Synthetic biology, Breeding, Research, Technology, Industry, Central, Fermentation, Department of Industry, Innovation, Climate Change, Science, Research and Tertiary Education, Human, Fine chemical

WUHAN, China, Oct. 20, 2022 /PRNewswire/ --On October 19th, 2022, the investment project of the CABIO R&D Center officially commenced in Wuhan Optical Valley.

Key Points: 
  • WUHAN, China, Oct. 20, 2022 /PRNewswire/ --On October 19th, 2022, the investment project of the CABIO R&D Center officially commenced in Wuhan Optical Valley.
  • Upon the basis of the said investment project, the ground-breaking ceremony of the "Wuhan Synthetic Biology Innovation Center" project, a joint endeavor between CABIO Biotech (Wuhan) Co., Ltd, the Wuhan Institute of Industrial Innovation and Development and Hubei Yangtze Science Innovation Service Co. Ltd., was also held on the same day.
  • The Wuhan Synthetic Biology Innovation Center has been envisioned as the spearhead of the synthetic biology industry of the entire Central China region.
  • In light of advancements in synthetic biology, CABIO has increased investment in said field, constructed a synthetic biology lab, and initiated a series of technologically far-sighted research projects teeming with market potential.

Datasea’s Ultrasonic Sound Sterilization and Antivirus Equipment Confirmed by Leading Lab Achieved a 99.83% Efficacy in Nine Seconds Against Covid-19

Retrieved on: 
Thursday, July 21, 2022
Virus, Shenzhen, Wuhan Institute of Virology, Infection, Severe acute respiratory syndrome coronavirus 2, Digital technology, Bacteria, GLOBE, School, U.S. Securities and Exchange Commission, CEO, Partnership, Private Securities Litigation Reform Act, Institute, Securities Exchange Act of 1934, Sterilization, Communications and Information Technology Commission (Saudi Arabia), COVID-19, NASDAQ, News, OXO-biodegradation, UV, Company, Beijing Science and Technology University Gymnasium, Device, Chinese Academy of Sciences, Life, Efficiency, Terminology, Disinfectant, Science, Pharmaceutical industry, Mobile phone, Virology

The test results, from the test which the Company paid the Institute to conduct, show that Dataseas Ultrasonic Sound Sterilization and Antivirus Equipment (the Device) has achieved 99.83% disinfection with SARS-CoV-2 (the virus that is known to cause COVID-19) in just nine seconds.

Key Points: 
  • The test results, from the test which the Company paid the Institute to conduct, show that Dataseas Ultrasonic Sound Sterilization and Antivirus Equipment (the Device) has achieved 99.83% disinfection with SARS-CoV-2 (the virus that is known to cause COVID-19) in just nine seconds.
  • The market need for sterilization devices has gained greater urgency because of the global coronavirus pandemic, as effective sterilization practices can curtail the spread of infectious diseases.
  • We believe that Datasea can bring substantial benefits and help reduce infection transmission in a wide range of application scenarios.
  • Todays announcement exemplifies the continued progress we have achieved with the commitment and dedication in the acoustic intelligence area.

Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples

Retrieved on: 
Thursday, July 14, 2022
ITM, LinkedIn, Safety, Byte Beautiful: Eight Science Fiction Stories, Wuhan Institute of Virology, Twitter, PCR, Instagram, DNA sequencing, View, Institute, Multimedia, Research, University Medical Center Freiburg, Monkeypox virus, Monkeypox, Transport, Collection, NGS, Solution, COVID-19, Infection, Vaccine, Facebook, Virology

This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.

Key Points: 
  • This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.
  • The DNA/RNA Shield product line includes sample collection, preservation, and transportation devices for specimens used in research and infectious disease testing workflows.
  • DNA/RNA Shield has enabled researchers to conduct infectious disease research and testing over the past decade, including throughout the COVID-19 pandemic.
  • Zymo Research offers several devices that can be filled with DNA/RNA Shield, including the popular SafeCollect Swab Collection Kit.